AR123078A1 - Medicamentos antiplaquetarios y usos de estos - Google Patents
Medicamentos antiplaquetarios y usos de estosInfo
- Publication number
- AR123078A1 AR123078A1 ARP210102107A ARP210102107A AR123078A1 AR 123078 A1 AR123078 A1 AR 123078A1 AR P210102107 A ARP210102107 A AR P210102107A AR P210102107 A ARP210102107 A AR P210102107A AR 123078 A1 AR123078 A1 AR 123078A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkynyl
- heteroalkenyl
- heteroalkyl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente divulgación se refiere a compuestos que exhiben actividad en la inhibición de la agregación plaquetaria, así como a composiciones farmacéuticas que comprenden estos compuestos y métodos de tratamiento de enfermedades vasculares mediante la administración de estos compuestos o las composiciones farmacéuticas. Reivindicación 1: Un compuesto que tiene la fórmula (1) o una sal farmacéuticamente aceptable de este, caracterizado porque ~~~¾ representa un enlace doble en configuración Z o E; R¹ se selecciona del grupo que consiste en hidrógeno, halógeno, nitro, ciano, hidroxilo, amino, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo y heteroalquinilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo y heteroalquinilo se sustituye opcionalmente con uno o más de un Rᵃ; R² es -C(O)Rᵇ; R³ se selecciona del grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye opcionalmente con ciano, halógeno, hidroxilo, amino, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo o heteroalquinilo; L se selecciona del grupo que consiste en un enlace directo, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye opcionalmente con uno o más de un Rᶠ; W se selecciona del grupo que consiste en: el grupo de fórmulas (2), donde el extremo * de W está conectado a L; R⁴ se selecciona del grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye opcionalmente con ciano, halógeno, hidroxilo, amino, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo o heteroalquinilo; cada Rᵃ se selecciona independientemente del grupo que consiste en hidrógeno, halógeno, hidroxilo, amino, ciano, nitro o -NRᶜRᵈ; Rᵇ se selecciona del grupo que consiste en hidrógeno, hidroxilo, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo, heteroarilo, -NRᶜRᵈ y -ORᵉ; cada Rᶜ y Rᵈ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, arilo y heteroarilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, arilo y heteroarilo se sustituye opcionalmente con ciano, halógeno, hidroxilo o amino; Rᵉ se selecciona del grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo, donde cada alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye opcionalmente con ciano, halógeno, hidroxilo, amino, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo o heteroalquinilo; cada Rᶠ se selecciona independientemente del grupo que consiste en hidrógeno, ciano, halógeno, hidroxilo, amino, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo; o dos Rᶠ, junto con el átomo al que los dos están unidos, forman un cicloalquilo saturado o parcialmente insaturado o un heterociclilo saturado o parcialmente insaturado, donde cada cicloalquilo y heterociclilo se sustituye opcionalmente con ciano, halógeno, hidroxilo, amino y alquilo; Rᵍ se selecciona del grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo saturado o parcialmente insaturado, heterociclilo saturado o parcialmente insaturado, arilo y heteroarilo, donde cada hidrógeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye opcionalmente con ciano, halógeno, hidroxilo o amino; n es 0, 1, 2, 3, 4 ó 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020105513 | 2020-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123078A1 true AR123078A1 (es) | 2022-10-26 |
Family
ID=80037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102107A AR123078A1 (es) | 2020-07-29 | 2021-07-29 | Medicamentos antiplaquetarios y usos de estos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410132B2 (es) |
| EP (2) | EP4188935A4 (es) |
| JP (1) | JP2023535815A (es) |
| KR (2) | KR20230047425A (es) |
| CN (4) | CN119033782B (es) |
| AR (1) | AR123078A1 (es) |
| AU (1) | AU2021317436A1 (es) |
| BR (1) | BR112023001595A2 (es) |
| CA (1) | CA3186645A1 (es) |
| ES (1) | ES3046366T3 (es) |
| IL (1) | IL299979A (es) |
| MX (1) | MX2023001232A (es) |
| TW (1) | TW202214609A (es) |
| WO (1) | WO2022022559A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532A (zh) * | 2023-06-29 | 2023-09-29 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334389A (en) * | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| AU2005259735A1 (en) * | 2004-07-07 | 2006-01-12 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| CN106554368A (zh) | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
-
2021
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 US US18/018,576 patent/US12410132B2/en active Active
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 ES ES24156405T patent/ES3046366T3/es active Active
- 2021-07-28 CN CN202411716601.2A patent/CN119552111B/zh active Active
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko active Pending
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 EP EP24156405.3A patent/EP4342532B1/en active Active
- 2021-07-28 JP JP2023506150A patent/JP2023535815A/ja active Pending
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-28 KR KR1020257016343A patent/KR102906376B1/ko active Active
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en not_active Ceased
- 2021-07-29 TW TW110127818A patent/TW202214609A/zh unknown
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
-
2025
- 2025-07-08 US US19/262,108 patent/US20250333382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023001595A2 (pt) | 2023-04-04 |
| CN116194459A (zh) | 2023-05-30 |
| MX2023001232A (es) | 2023-05-15 |
| EP4342532A2 (en) | 2024-03-27 |
| ES3046366T3 (en) | 2025-12-01 |
| EP4188935A1 (en) | 2023-06-07 |
| EP4342532C0 (en) | 2025-09-03 |
| TW202214609A (zh) | 2022-04-16 |
| WO2022022559A1 (en) | 2022-02-03 |
| KR20250073569A (ko) | 2025-05-27 |
| CN119033782A (zh) | 2024-11-29 |
| US20240279178A1 (en) | 2024-08-22 |
| EP4188935A4 (en) | 2024-07-17 |
| EP4342532A3 (en) | 2024-07-17 |
| IL299979A (en) | 2023-03-01 |
| AU2021317436A1 (en) | 2023-02-23 |
| JP2023535815A (ja) | 2023-08-21 |
| CN119033782B (zh) | 2025-04-25 |
| CN119552111A (zh) | 2025-03-04 |
| US20250333382A1 (en) | 2025-10-30 |
| CN117343000A (zh) | 2024-01-05 |
| CA3186645A1 (en) | 2022-02-03 |
| US12410132B2 (en) | 2025-09-09 |
| CN119552111B (zh) | 2026-01-02 |
| KR102906376B1 (ko) | 2025-12-30 |
| EP4342532B1 (en) | 2025-09-03 |
| KR20230047425A (ko) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123078A1 (es) | Medicamentos antiplaquetarios y usos de estos | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| PE20241476A1 (es) | Inhibidores de la ras | |
| AR121669A1 (es) | Compuesto de piridazina sustituida | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| PE20230673A1 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| PE20240775A1 (es) | Compuestos antivirales | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| ECSP12011695A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| PE20230601A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR088414A1 (es) | Derivados sustituidos de indol | |
| AR124582A1 (es) | Compuestos de aminotiazol como inhibidores de c-kit | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
| AR119341A1 (es) | Profármacos de moduladores del receptor de nmda | |
| AR127255A1 (es) | NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM | |
| AR124451A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES |